Table 4.

Results of the multiple regression analyses: EORTC QLQ-MY20 subscales with (95 % confidence interval)

Parameter	Disease Symptoms	Future Perspective
Bone pain
Moderate vs. mild/none	18.08 (10.77; 25.38)*	NS
Severe vs. mild/none	37.54 (27.77; 47.31)*	NS
Depression (yes vs. no)	NS	−20.11 (−32.31; −7.92)*
Sleepiness (yes vs. no)	NS	−13.32 (−22.14; −4.50)*
Muscle cramps (mild/moderate vs. none)	10.80 (−0.71; 22.32)	NS
Headache (yes vs. no)	NS	−13.25 (−24.93; −1.57)*
German descent	NS	−11.82 (−20.40; −3.23)*
Sex (female vs. male)	9.63 (3.85; 15.41)*	NS
Type of current treatment
Bortezomib containing vs. none	NS	−10.13 (−20.30; 0.04)
Lenalidomide containing vs. none	NS	−11.63 (−25.10; 1.85)
Thalidomide containing vs. none	NS	0.64 (−13.57; 14.85)
Alkylating agents containing/other vs. none	NS	−6.33 (−22.50; 9.85)
Duration of current treatment	0.02 (0.00; 0.03)	NS

NS not significant at 0.1 level (i.e., P value of >0.1), NA not applicable

*P value of <0.05